Table 1.
Baseline characteristics of participants (N=163) in the OmniCarb trial
| Characteristics | Mean (SD) or n (%) |
| Age, years | 52.6 (11.4) |
| Women, % | 85 (52) |
| Race, % | |
| Non-Hispanic African–American | 66 (40) |
| Non-Hispanic white | 82 (50) |
| Hispanic | 11 (7) |
| Asian | 4 (2) |
| Lactate, mmol/L | 1.2 (0.5) |
| Body mass index, kg/m2 | 32.3 (5.5) |
| Body mass index, % | |
| 25–29.9 | 71 (44) |
| ≥30 | 92 (56) |
| Waist circumference, cm | 104.4 (13.5) |
| Serum fasting glucose, mg/dL | 97.3 (13.6) |
| Serum 2-hour glucose, mg/dL | 135.4 (42.6) |
| Serum fasting insulin, μU/mL | 7.7 (5.8) |
| Serum 2-hour insulin, μU/mL | 48.8 (43.1) |
| Impaired fasting glucose (serum fasting glucose ≥100 mg/dL), % | 58 (35.6) |
| Homeostasis model assessment, units | 1.9 (1.6) |
| HDL cholesterol, mg/dL | 58.3 (16.0) |
| LDL cholesterol, mg/dL | 153.0 (42.1) |
| Triglycerides, mg/dL | 104.6 (67.1) |
| SBP, mm Hg | 132.0 (9.1) |
| DBP, mm Hg | 80.0 (7.5) |
| Baseline hypertensive status*, % | |
| Non-hypertensive | 120 (74) |
| Hypertensive | 43 (26) |
*Defined as baseline SBP ≥140 or DBP ≥90 mm Hg.
DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SBP, systolic blood pressure.